Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Anita Boyapati · SciRah

Researcher profile · Semantic Scholar

Anita Boyapati

Share profile

Anita Boyapati — researcher profile on SciRah

h-index: 21
Works: 61
Citations: 1,643

Most-cited papers

A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis
Ming Yan, E. Kanbe, L. Peterson, Anita Boyapati +7 more
2006Nature Medicine321 citations
Semantic Scholar
SON Controls Cell Cycle Progression by Coordinated Regulation of RNA Splicing
Eun-young Ahn, Russell Dekelver, Miao-Chia Lo, Tuyet Nguyen +5 more
2011Molecules and Cells163 citations Open access
Semantic Scholar
Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development.
Ming Yan, S. Burel, L. Peterson, E. Kanbe +5 more
2004Proceedings of the National Academy of Sciences of the United States of America150 citations Open access
Semantic Scholar
Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.
L. Peterson, Anita Boyapati, Eun-young Ahn, J. Biggs +4 more
2007Blood122 citations Open access
Semantic Scholar
Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis
Eun-young Ahn, Ming Yan, O. Malakhova, Miao-Chia Lo +5 more
2008Proceedings of the National Academy of Sciences of the United States of America70 citations Open access
Semantic Scholar
The Hematopoietic Transcription Factor AML1(RUNX1) Is Negatively Regulated by the Cell Cycle ProteinCyclinD3
L. Peterson, Anita Boyapati, V. Ranganathan, A. Iwama +3 more
2005Molecular and Cellular Biology59 citations Open access
Semantic Scholar
REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
D. Madduri, A. Rosko, J. Brayer, J. Zonder +16 more
2020Blood53 citations Open access
Semantic Scholar
LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.
Hans C. Lee, N. Bumma, J. Richter, M. Dhodapkar +16 more
2023Journal of Clinical Oncology51 citations
Semantic Scholar
Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial
M. Dirocco, E. Forleo-Neto, R. Pignolo, R. Keen +32 more
2023Nature Medicine50 citations Open access
Semantic Scholar
Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY
Anita Boyapati, J. Msihid, S. Fiore, J. van Adelsberg +2 more
2016Arthritis Research & Therapy50 citations Open access
Semantic Scholar
Association of High Serum Interleukin‐6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis
Anita Boyapati, S. Schwartzman, J. Msihid, E. Choy +8 more
2020Arthritis & Rheumatology45 citations Open access
Semantic Scholar
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
C. Gabay, G. Burmester, V. Strand, J. Msihid +7 more
2020Arthritis Research & Therapy44 citations Open access
Semantic Scholar
3-Phosphoinositide–Dependent Protein Kinase-1 Regulates Proliferation and Survival of Cancer Cells with an Activated Mitogen-Activated Protein Kinase Pathway
Zhuomei Lu, Mary Ann Cox-Hipkin, W. Windsor, Anita Boyapati
2010Molecular Cancer Research43 citations
Semantic Scholar
Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
D. Cooper, D. Madduri, S. Lentzsch, S. Jagannath +11 more
2019Blood38 citations
Semantic Scholar
Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
J. Zonder, J. Richter, N. Bumma, J. Brayer +13 more
2021Blood36 citations Open access
Semantic Scholar
High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab
V. Strand, S. Boklage, T. Kimura, F. Joly +2 more
2020Arthritis Research & Therapy36 citations Open access
Semantic Scholar
Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study
C. Gabay, J. Msihid, M. Zilberstein, C. Paccard +3 more
2018RMD Open36 citations Open access
Semantic Scholar
A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy.
Anita Boyapati, Ming Yan, L. Peterson, J. Biggs +2 more
2007Blood33 citations Open access
Semantic Scholar
SV40 17KT antigen complements dnaj mutations in large T antigen to restore transformation of primary human fibroblasts.
Anita Boyapati, M. Wilson, Jing Yu, K. Rundell
2003Virology33 citations Open access
Semantic Scholar
Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
N. Bumma, J. Richter, J. Brayer, J. Zonder +16 more
2022Blood32 citations Open access
Semantic Scholar
Baseline Severe Acute Respiratory Syndrome Viral Load Is Associated With Coronavirus Disease 2019 Severity and Clinical Outcomes: Post Hoc Analyses of a Phase 2/3 Trial
Anita Boyapati, M. Wipperman, Peter J. Ehmann, S. Hamon +9 more
2021Journal of Infectious Diseases24 citations Open access
Semantic Scholar
Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate
Anne J. Paccaly, P. Kovalenko, J. Parrino, Anita Boyapati +5 more
2020Journal of clinical pharmacology19 citations Open access
Semantic Scholar
Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial
S. Sivapalasingam, D. Lederer, R. Bhore, N. Hajizadeh +36 more
2022Clinical Infectious Diseases14 citations Open access
Semantic Scholar
Association of complement pathways with COVID-19 severity and outcomes
K. Devalaraja-Narashimha, Peter J. Ehmann, Cong Huang, Q. Ruan +12 more
2022Microbes and infection14 citations Open access
Semantic Scholar
Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis
P. Kovalenko, A. Paccaly, Anita Boyapati, Christine R. Xu +5 more
2020CPT: Pharmacometrics & Systems Pharmacology10 citations Open access
Semantic Scholar
SERPINB13 is a novel RUNX1 target gene
Anita Boyapati, B. Ren, Dong-Er Zhang
2011Biochemical and Biophysical Research Communications - BBRC10 citations Open access
Semantic Scholar
p53 Alterations in Myeloid Leukemia
Anita Boyapati, E. Kanbe, Dong-Er Zhang
2003Acta Haematologica10 citations
Semantic Scholar
Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO.
R. Hines, Anita Boyapati, Dong-Er Zhang
2007Blood Cells, Molecules & Diseases9 citations Open access
Semantic Scholar
Activin A correlates with the worst outcomes in COVID-19 patients, and can be induced by cytokines via the IKK/NF-kappa B pathway
Megan McAleavy, Qian Zhang, Jianing Xu, L. Pan +9 more
2021bioRxiv8 citations Open access
Semantic Scholar
069 High baseline serum IL-6 identifies a subgroup of rheumatoid arthritis patients with rapid joint damage and clinical progression and predicts increased sarilumab treatment response
Anita Boyapati, J. Msihid, S. Schwartzman, E. Choy +5 more
2019Rheumatology7 citations
Semantic Scholar
AB0472 Pharmacodynamic effect and safety of single-dose sarilumab sc or tocilizumab iv or sc in patients with rheumatoid arthritis (RA)
T. Ishii, Y. Sato, Y. Munakata, M. Kajiwara +7 more
2018Rheumatoid arthritis – biological DMARDs7 citations Open access
Semantic Scholar
S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Hans C. Lee, N. Bumma, J. Richter, M. Dhodapkar +16 more
2023HemaSphere6 citations Open access
Semantic Scholar
The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients
Megan McAleavy, Qian Zhang, Peter J. Ehmann, Jianing Xu +13 more
2021Molecular and Cellular Biology6 citations Open access
Semantic Scholar
A phase I/II study of REGN5093, a MET x MET bispecific antibody, in patients with MET-altered advanced non-small cell lung cancer (NSCLC).
T. Rowlands, Anita Boyapati, Siyu Li, C. Daly +3 more
20206 citations
Semantic Scholar
PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
K. Weisel, V. Hungria, H. Quach, S. Yoon +11 more
2023HemaSphere5 citations Open access
Semantic Scholar
FRI0227 Sarilumab significantly suppresses circulating biomarkers of bone resorption and cardiovascular risk compared with adalimumab: biomarker analysis from the phase 3 monarch study
C. Gabay, J. Msihid, C. Paccard, M. Zilberstein +2 more
20175 citations Open access
Semantic Scholar
Acute Myeloid Leukemia with the 8 q 22 ; 21 q 22 Translocation : Secondary Mutational Events and Alternative t
Anita Boyapati, Eun-young Ahn, J. Biggs, A. Okumura +3 more
20074 citations
Semantic Scholar
MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma.
J. Zonder, J. Richter, N. Bumma, J. Brayer +14 more
2022Clinical Lymphoma, Myeloma & Leukemia3 citations
Semantic Scholar
UGT1A1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab
N. Lin, A. Damask, Anita Boyapati, J. Hamilton +11 more
2017The Pharmacogenomics Journal3 citations Open access
Semantic Scholar
Trial in Progress: A Phase II Window of Opportunity Study of the BCMAxCD3 Bispecific Antibody REGN5458 in Previously Untreated Patients with Symptomatic Multiple Myeloma
Christopher J. Ferreri, Steven E. Quatela, Sean Aina, Pourab Roy +4 more
2022Blood2 citations Open access
Semantic Scholar
Pharmacodynamic (PD) Model of Neutrophil Margination to Describe Transient Effect of Single-Dose Sarilumab on Absolute Neutrophil Count (ANC) in Patients With Rheumatoid Arthritis (RA)
P. Kovalenko, A. Paccaly, Anita Boyapati, Christine R. Xu +2 more
20172 citations
Semantic Scholar
AML1-ETO9a, an Alternatively Spliced Form of AML1-ETO, Collaborates with AML1-ETO To Promote Leukemogenesis.
Ming Yan, Yang Wang, L. Peterson, E. Kanbe +2 more
20052 citations
Semantic Scholar
Baseline SARS-CoV-2 Viral Load Is Associated with Disease Severity and Clinical Outcomes in Hospitalised Patients with COVID-19: Post-Hoc Analyses of a Phase 2/3 Multicentre Trial
Anita Boyapati, M. Wipperman, Peter J. Ehmann, S. Hamon +9 more
20211 citations Open access
Semantic Scholar
FRI0120 HIGH LEVELS OF INTERLEUKIN-6 (IL-6) IN RA PATIENTS ARE ASSOCIATED WITH GREATER IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES (PROS) FOR SARILUMAB COMPARED WITH ADALIMUMAB
V. Strand, S. Boklage, T. Kimura, F. Joly +2 more
2019Poster Presentations1 citations
Semantic Scholar
An alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis
Dong-Er Zhang, Ming Yan, Anita Boyapati
20061 citations Open access
Semantic Scholar
PB2144: TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA
Christopher J. Ferreri, Steven E. Quatela, Oluwaseun Aina, Pourab Roy +4 more
2023HemaSphere0 citations Open access
Semantic Scholar
OAB-056: Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multiple myeloma
J. Zonder, J. Richter, N. Bumma, J. Brayer +14 more
2022Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
P-064: Heterogeneity of bone marrow biopsy and bone marrow aspirate (BMA) in patients with heavily pretreated relapsed/refractory Multiple Myeloma (RRMM)
Anita Boyapati, N. Fiaschi, M. Dhodapkar, S. Jagannath +7 more
2021Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
5 Multiple myeloma flow cytometry panel validated for clinical monitoring of patients
Bevan P. Gang, Vicky Sgouroudis, V. Litwin, Anita Boyapati
2020Journal for ImmunoTherapy of Cancer0 citations Open access
Semantic Scholar
P213 High baseline serum IL-6 predicts increased sarilumab treatment response for patient reported symptoms and health-related quality of life among RA patients with inadequate response to MTX
V. Strand, J. Msihid, T. Kimura, Anita Boyapati +2 more
20200 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Dong-Er Zhang×13
Invite
Dong-Er Zhang — researcher profile on SciRah
G. Kroog×10
Invite
G. Kroog — researcher profile on SciRah
J. Msihid×9
Invite
J. Msihid — researcher profile on SciRah
Ming Yan×8
Invite
Ming Yan — researcher profile on SciRah

×8

Invite

J. Zonder — researcher profile on SciRah

Invite

D. Chokshi — researcher profile on SciRah

M. Dhodapkar×8

Invite

M. Dhodapkar — researcher profile on SciRah

Invite

S. Lentzsch — researcher profile on SciRah

S. Jagannath×8

Invite

S. Jagannath — researcher profile on SciRah

Invite

L. Peterson — researcher profile on SciRah

Invite

N. Bumma — researcher profile on SciRah

Invite

J. Richter — researcher profile on SciRah